ST. PETERSBURG, Fla., July 14, 2023 (Newswire.com) - GOBEL, the world's leading consulting and technology firm working exclusively for healthcare philanthropy, is pleased to announce that it has been awarded a second patent from the U.S. government related to its innovative Gratitude to Give™ (G2G) predictive modeling technology. G2G is four to five times more likely to forecast who will give compared to traditional wealth-screening models. 

"We have long believed that gratitude drives the decision to give and wealth drives how much someone gives. Last year's patent awarded by the U.S. government was a milestone for our company, but also for all our clients who have long pursued the next level of fundraising, the kind of revenue generation that G2G realizes," said Chad Gobel, founder and CEO. "It was the first step on this journey to formalize our breakthrough methodology and technology. This second patent is an enormous next step."

GOBEL developed G2G as the first AI and ML fundraising model that identifies signs of gratitude by analyzing affinity and experiential data rather than wealth data alone. The sophisticated Gratitude to Give technology helps healthcare clients like hospitals, hospices and academic research institutes raise more money by predicting and segmenting patient populations, identifying the best prospects for annual, planned and major gift prospects, and creating the highest ROI by pinpointing the best prospects. It provides direct visibility into a patient's unique experience and uses big data sets to determine likelihood to give. Results are presented in one easy-to-use platform that offers multiple views so users can identify the best prospects for high wealth and high gratitude.

The original award last July was a patent on generating gratitude scores, using a machine-learning model. The new patent covers more products using machine-learning models to identify gratitude.

"This next step in predictive modeling involves the use of more and current data in real time," said Chad Gobel. "As people's information changes, our models change to stay as current as possible. Effective fundraising in the healthcare — or any — industry relies on keeping pace with change. These models will better and more thoroughly refine the information we provide for clients about their current and potential donors."

For more information, contact Grace Castilow, Public Relations Manager, at [email protected]. 

About GOBEL

GOBEL is the world's leading consulting and technology firm in healthcare philanthropy. We offer clients the most comprehensive solution for building a robust philanthropy program, using data and analytics to advise clients in organizational assessments, campaigns, grateful patient programs, major gifts and clinical training, and more. GOBEL also provides clients with primary and secondary research, along with peer analysis and benchmarking. Our team of 50+ seasoned healthcare development professionals and clinicians comes from the top medical centers in the nation. We bring more than 750 years of collective healthcare philanthropy experience to our client engagements and have worked with over 1,000 hospitals and health systems in our history.

EuCorVac-19
EuCorVac-19, a recombinant protein vaccine displaying the SARS-CoV-2 receptor-binding domain (RBD) antigen on the immunogenic liposomes

BUFFALO, N.Y., July 14, 2023 (Newswire.com) -  POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical startup, announces top line interim results of a Phase 3 clinical trial of EuCorVac-19, a COVID-19 vaccine candidate being developed by South Korean partner EuBiologics (KOSDAQ: 206650). EuCorVac-19 is a protein-based vaccine consisting of a vaccine antigen displayed on immunogenic nanoparticles, using POP BIO's spontaneous-nanoliposome antigen particle (SNAP) technology.

The phase 3 trial of EuCorVac-19 was conducted in the Philippines in approximately 2,600 adults (NCT05572879). EuCorVac-19 demonstrated superior antibody immunogenicity compared to a World Health Organization Emergency Use Authorized adenoviral vector vaccine, thereby meeting the primary endpoint of the phase 3 trial.

The formation of neutralizing antibodies, which prevent COVID-19 infection, was more than twice as high in EuCorVac-19 compared to the control vaccine. EuCorVac-19 exhibited a high serological response rate with neutralizing antibody titers increasing after vaccination. In particular, the neutralizing antibody titers and serum response rates in subjects aged over 65 exceeded those of the control vaccine. In immunogenicity analysis against the Omicron BA.5 strain, EuCorVac-19 induced more than twice the neutralizing antibody titer compared to the control vaccine.

EuCorVac-19's safety profile was further established in this phase 3 study. EuCorVac-19 showed a slightly lower incidence than the control vaccine of solicited adverse events and there was no difference between EuCorVac-19 and the control vaccine in the incidence of unsolicited adverse events.

These results further validate the strength and synergy of POP BIO's SNAP and EuBiologics' EuIMT platform technologies used in the EuCorVac-19 vaccine. Further development of booster vaccines, new strain vaccines, and combination vaccines for COVID-19 will be significantly more straightforward in the future. 

"Achieving the completion of this Phase III trial is an enormous milestone for our technologies. These results provide validation towards not only solving this unprecedented global crisis but also provides invaluable support towards our platform's development, further enabling the creation of new vaccines with tremendous potential to alleviate suffering worldwide," said POP BIO co-founder Jonathan Smyth.

EuCorVac-19 was already shown to be safe and immunogenic in a Phase I/II clinical trial, the results of which were announced in December 2021. The Philippine Phase 3 trial, conducted since third quarter of 2022, were supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the ministry of Health & Welfare, Republic of Korea.

Based on the results of this clinical study, EuBiologics plans to apply for product approval in the Philippines shortly. Later this year, results will become available from a second independent Phase 3 clinical study being carried out in the Democratic Republic of Congo.

About POP Biotechnologies: POP Biotechnologies, Inc. is a privately held biotechnology company focused on the research and development of novel therapeutics and vaccines employing their proprietary porphyrin-phospholipid (PoP) liposome technologies. The PoP technology, exclusively licensed from the State University of New York Research Foundation (SUNY-RF), was developed by company co-founder Dr. Jonathan Lovell at his academic facilities at The State University of New York at Buffalo (SUNY Buffalo). POP Biotechnologies is currently a resident of the SUNY Buffalo incubator at Baird Research Park.

About POP BIO's SNAP Technology: POP BIO's Spontaneous Nanoliposome Antigen Particleization (SNAP) technology enables the rapid development and manufacturing of highly immunogenic particle-based vaccines and immunotherapies directed against infectious disease and cancer through the use of a cobalt modified variant of the PoP technology (CoPoP). The SNAP technology enables the seamless generation of stable particle-formation and liposome-display of protein and peptide antigens resulting in substantial improvements in immune responses.

About EuBiologics: EuBiologics is a South Korean Biotechnology company that is advancing the EuCorVac-19 COVID-19 vaccine and other vaccine products. EuBiologics has two main animal-based bioreactors (1,000L) to produce recombinant protein antigens at Chuncheon Plant 1(C-Plant) and EcML(Monophosphoryl Lipid A) which is adjuvant at Chuncheon Plant 2(V-Plant). The total capacity of the COVID-19 vaccine is currently in the hundreds of millions of doses per year.

About EuBiologics' EuIMT Technology: EuBioloigcs' Immune Modulation Technology using genetically engineered Monophosphoryl Lipid A (MLA), called EcML that is a unique TLR4 agonist. EuBiologics has IP protection around EcML and various adjuvant systems including EcML. Eubiologics' EcML and POP BIO's SNAP technologies synergize to create ultrapotent next-generation vaccines.

Victoria Headshot
Chief Growth Officer-RCM Solutions of SupportDDS

ARGYLE, Texas, July 14, 2023 (Newswire.com) - SupportDDS is pleased to announce the appointment of Victoria Johnson as the new Chief Growth Officer, RCM Solutions. With over a decade of experience, she has served in progressive leadership roles in dental practices and DSOs specializing in strategy, optimization and implementation of the entire revenue cycle operation. 

Prior to joining SupportDDS, Johnson held various leadership positions at several prominent companies in the industry, including her most recent position as Senior Vice President of Revenue Cycle Management at Select Dental Management. She has a proven track record built on the pillars of creating high-performance cultures, patient satisfaction, operational systems, and practice efficiency.

Johnson is a proud graduate of NC State University. She currently resides in Dallas, Texas, with her husband Jace and two children, Colt and Olivia.

SAN DIEGO, July 14, 2023 (Newswire.com) - Taking care of one's physical well-being is essential on the road to addiction recovery. For the men at Shoreline Recovery Center and Park Mental Health, self-care plays a crucial role. It's through the tailored guidance received from counselors, therapists and support groups that they become self-sustaining individuals.

"We believe that in order to heal and have therapy be the most effective, intentional self-care alongside addiction treatment is essential for recovery," said Mikayla Weathers, Program Director and LMFT at Park Mental Health. "This includes maintaining regular exercise, getting enough sleep, eating a balanced diet and avoiding substances that could trigger a relapse."

When it comes to addiction recovery, men are up against a host of obstacles. Beginning with their emotional well-being, they often face unfair expectations, such as suppressing feelings to remain strong in difficult circumstances.

"Most men have been taught through societal conditioning that having and showing emotions equates to weakness…" Weathers said. "This is why we start by acknowledging how they've been taught to deal with emotions in their childhood and how processing emotions was modeled to them, in order to help them build insight into why they may struggle with this."

Recovery from addiction is often an arduous journey with highs, lows and setbacks, so stress management is a significant aspect of addiction recovery. Regular self-reflection for example, is a tool that can help in understanding triggers, identifying patterns and setting meaningful goals. It's important that time is taken to assess progress, celebrate achievements and adjust things as necessary.

"In early recovery, clients struggle with self-compassion, positive self-talk and self-forgiveness due to the shame and guilt they carry because of their actions during addiction and/or mental health crisis. We normalize each client's emotions and encourage them to shift old patterns of holding onto them to talking about them in peer groups and therapy sessions instead," Weathers said. Often times they haven't been taught how to put their experience into words, which is why psychoeducation is used to teach them about feelings.

Setting realistic short and long-term goals can provide a sense of purpose and direction. Shoreline Recovery Center and Park Mental Health have curriculum groups and therapy sessions to encourage open communication, self-reflection and weekly goal setting.

In addition to self-care and reflection, cultivating healthy relationships and cutting the cord on toxic ones is vital during addiction recovery, which is why staff hold clients accountable to falling back into old patterns and encourage them to make different decisions when it comes to the people they surround themselves with. These men need to have people in their lives who understand and respect their journey.

"Recovery is affected and influenced by every dimension of life, which includes personal and community relationships. Developing healthy relationships, social skills, habits and effective communication skills are an important part of maintaining long-term stability," Weathers said.